Adjuvant chemotherapy for breast cancer and fertility: Estimation of the impact, options of preservation and role of the oncologist;Chimiothérapie adjuvante de cancer du sein et fertilité: Estimation de l'impact, options de préservation et place de l'oncologue

Bulletin du Cancer

Volumn 98, Issue 7, 2011, Pages 741-751

  Mailliez, Audrey ^a   Decanter, Christine ^b   Bonneterre, Jacques ^a,b,c  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

Author keywords

Amenorrhea; Breast cancer; Chemotherapy; Fertility preservation; In vitro maturation (IVM); Ovarian cryopreservation

Indexed keywords

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CRYOPRESERVATION; FEMALE INFERTILITY; FERTILITY; HUMAN; IN VITRO STUDY; MEDICAL ETHICS; OOCYTE MATURATION; OVARIAN RESERVE; PROGENY; PROGNOSIS; REPRODUCTION; RISK ASSESSMENT;

EID: 79960491625     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1391     Document Type: Article

References (72)

1. Guerin S, Hill C. Ĺpidémiologie des cancers en France en 2010 : comparaison avec les États-Unis. Bull Cancer 2010 ; 97 : 47-54.
2. Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr 1994 ; 16 : 7-14.
3. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004 ; 10 : 3249-61. (Pubitemid 38685428)
4. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005 ; 352 : 2302-13. (Pubitemid 40740554)
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 ; 365 : 1687-717.
6. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005 ; 11 : 69-89. (Pubitemid 40201977)
7. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007 ; 30 : 126-32. (Pubitemid 46573245)
8. Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed- by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009 ; 113 : 315-20.
9. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990 ; 1 : 183-8. (Pubitemid 20218533)
10. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986 ; 1 : 5-9.
11. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005 ; 104 : 1575-9. (Pubitemid 41437419)
12. Berlière M, Dalenc F, Malingret N, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008 ; 8 : 56.
13. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 2008 ; 90 : 1635-9.
14. Han HS, Ro J, Lee KS, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 2009 ; 115 : 335-42.
15. Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín- Martorell P, Bermejo B. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat 2010 ; 120 : 245-51.
16. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009 ; 15 : 323-39.
17. Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006 ; 24 : 4044-6. (Pubitemid 46630768)
18. Larsen EC, Müller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiationand chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003 ; 88 : 5307-14. (Pubitemid 37452732)
19. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003 ; 18 : 2368-74. (Pubitemid 37427819)
20. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006 ; 21 : 2583-92. (Pubitemid 44542149)
21. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010 ; 20 : 280-5.
22. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 2010 ; 94 : 156-66.
23. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010 ; 116 : 592-9.
24. Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008 ; 26 : 286-95. (Pubitemid 351329008)
25. Yu B, Douglas N, Ferin MJ, et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010 ; 116 : 2099-105.
26. Rosen A. Third-party reproduction and adoption in cancer patients. J Natl Cancer Inst Monogr 2005 ; 34 : 91-3.
27. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer 1999 ; 86 : 697-709. (Pubitemid 29379417)
28. Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology 2004 ; 13 : 689-99. (Pubitemid 39378262)
29. United States. President's Cancer Panel. Meeting (2004: Philadelphia Pa.) and National Cancer Institute (U.S.), President's Cancer Panel meeting: living beyond cancer: meeting the challenges of older adult survivors: Philadelphia, Pennsylvania, January 2004. Bethesda, Md. (31 Center Dr., Room 3A-18 MSC 2440, Bethesda 20892-2440): National Cancer Institute, 2004, 197 p.
30. Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the youngwoman with cancer. J Natl Cancer Inst Monogr 2005 ; 34 : 57-9.
31. Olivennes F, Aubard Y. Treatment of cancer in women and fertility preservation. Bull Cancer 2002 ; 89 : 786-94. (Pubitemid 35177581)
32. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008 ; 26 : 2630-5.
33. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005 ; 23 : 3858-9.
34. Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 1973 ; 80 : 844-7.
35. Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod 2005 ; 20 : 1511-5. (Pubitemid 40852240)
36. AFSSAPS. Recommendations of good practice: medicines that induce ovulation (April 2004). Gynecol Obstet Fertil 2004 ; 32 : 829-33.
37. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006 ; 86 : 70-80. (Pubitemid 43962981)
38. Dessolle L, de Larouzière V, Ravel C, Berthaut I, Antoine JM, Mandelbaum J. Slow freezing and vitrification of human mature and immature oocytes. Gynecol Obstet Fertil 2009 ; 37 : 712-9.
39. Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugières L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 2002 ; 17 : 1447-52. (Pubitemid 34661789)
40. Newton H, Aubard Y, Rutherford A, Sharma V, Gosden R. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996 ; 11 : 1487-91. (Pubitemid 26335099)
41. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000 ; 342 : 1919. (Pubitemid 30419063)
42. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004 ; 364 : 1405-10. (Pubitemid 39370715)
43. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005 ; 353 : 318-21. (Pubitemid 41058339)
44. Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004 ; 363 : 837-40. (Pubitemid 38368830)
45. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001 ; 286 : 1490-3. (Pubitemid 33015506)
46. Roux C, Amiot C, Agnani G, Aubard Y, Rohrlich PS, Piver P. Live birth after ovarian tissue autograft in a patient with sickle cell disease treated by allogeneic bone marrow transplantation. Fertil Steril 2010 ; 93 : 2413 e15-9.
47. Rosendahl M, Loft A, Byskov AG, et al. Biochemical pregnancy after fertilization of an oocyte aspirated from a heterotopic autotransplant of cryopreserved ovarian tissue: case report. Hum Reprod 2006 ; 21 : 2006-9. (Pubitemid 44288073)
48. This P. Breast cancer and fertility: critical review, considerations and perspectives. Bull Cancer 2008 ; 95 : 17-25. (Pubitemid 351262479)
49. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006 ; 11 : 422-34. (Pubitemid 43788268)
50. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004 ; 10 : 251-66.
51. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005 ; 34 : 40-3.
52. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985 ; 45 : 3651-6. (Pubitemid 15226440)
53. Imai A, Furui T. Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues. J Obstet Gynaecol 2007 ; 27 : 20-4.
54. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005 ; 83 : 1333-8. (Pubitemid 40615801)
55. Meistrich ML. Failure to demonstrate hormonal protection of chemotherapy-induced fertility reduction in female rats. Reprod Toxicol 1994 ; 8 : 277-8.
56. Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction 2008 ; 136 : 691-701.
57. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008 ; 14 : 543-52.
58. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006 ; 106 : 514-23. (Pubitemid 43157613)
59. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006 ; 17 : 74-8. (Pubitemid 43033843)
60. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy - protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005 ; 66 : 77-82. (Pubitemid 40873982)
61. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann MLHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007 ; 369 : 1711-23.
62. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010 ; 122 : 803-11.
63. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 2005 ; 23 : 766-73. (Pubitemid 46224175)
64. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004 ; 22 : 4174-83. (Pubitemid 41185188)
65. Thewes B, Meiser B, Rickard J, Friedlander M. The fertilityand menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. Psychooncology 2003 ; 12 : 500-11. (Pubitemid 36873985)
66. Chabbert-Buffet N, Uzan C, Gligorov J, Delaloge S, Rouzier R, Uzan S. Pregnancy after breast cancer: a need for global patient care, starting before adjuvant therapy. Surg Oncol 2010 ; 19 : e47-55.
67. Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004 ; 100 : 465-9. (Pubitemid 38124762)
68. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". Am J Obstet Gynecol 1994 ; 170 : 818-23.
69. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007 ; 334 : 194.
70. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001 ; 19 : 980-91. (Pubitemid 32176272)
71. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the childhood cancer survivor study. Am J Obstet Gynecol 2002 ; 187 : 1070-80. (Pubitemid 35178413)
72. Sankila R, Olsen JH, Anderson H, et al. Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med 1998 ; 338 : 1339-44.